Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

ADC Toxin Monomethyl auristatin F (MMAF)

ADC Toxin Monomethyl auristatin F (MMAF)

Inquiry
Antimitotic agent used as toxin linked to antibody
Catalog No. Unit Price Qty
T60002-10s 10 mg solid $369.00

Details

Product Information
Molecular Weight: 731.96
Formula: C39H65N5O8
Purity: ≥95%
CAS#: 745017-94-1
Solubility: DMSO up to 20 mM
Chemical Name: (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid
Storage: Powder: -20oC 1 year

Biological Activity:

Monomethyl auristatin F (MMAF) is an anti-mitotic agent that inhibits cell division by blocking the polymerization of tubulin. It is a new auristatin derivative ith a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart MMAE. Because of its super toxicity, it cannot be used as a drug itself. It is linked to a monoclonal antibody (mAb) that directs it to the cancer cells. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism.

Reference:

  1. 1. Smith LM, et al. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. (2006)  Mol Cancer Ther. 5(6):1474-82
  2. 2. Doronina, SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. (2006) Bioconjug Chem, 17(1):114-24.
  3. 3. Oflazoglu E, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. (2008) Clin Cancer Res. 14(19):6171-80.
  4. 4. Nilsson R, et al. Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model. (2010) Cancer 116(4 Suppl):1033-42.
  5. 5. http://en.wikipedia.org/wiki/Monomethyl_auristatin_E

    MMAF_spec.pdf


Products are for research use only. Not for human use.

Description

Details

Product Information
Molecular Weight: 731.96
Formula: C39H65N5O8
Purity: ≥95%
CAS#: 745017-94-1
Solubility: DMSO up to 20 mM
Chemical Name: (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid
Storage: Powder: -20oC 1 year

Biological Activity:

Monomethyl auristatin F (MMAF) is an anti-mitotic agent that inhibits cell division by blocking the polymerization of tubulin. It is a new auristatin derivative ith a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart MMAE. Because of its super toxicity, it cannot be used as a drug itself. It is linked to a monoclonal antibody (mAb) that directs it to the cancer cells. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism.

Reference:

  1. 1. Smith LM, et al. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. (2006)  Mol Cancer Ther. 5(6):1474-82
  2. 2. Doronina, SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. (2006) Bioconjug Chem, 17(1):114-24.
  3. 3. Oflazoglu E, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. (2008) Clin Cancer Res. 14(19):6171-80.
  4. 4. Nilsson R, et al. Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model. (2010) Cancer 116(4 Suppl):1033-42.
  5. 5. http://en.wikipedia.org/wiki/Monomethyl_auristatin_E

    MMAF_spec.pdf


Products are for research use only. Not for human use.

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: